Understanding adjuvant endocrine therapy persistence in breast Cancer survivors

BACKGROUND: Adjuvant endocrine therapy (AET) significantly decreases the risk of breast cancer recurrence and mortality. Notwithstanding the demonstrated efficacy of AET, 31–73% of breast cancer survivors do not persist with AET. The purpose of this study was to explore breast cancer survivors’ expe...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Leah K., Balneaves, Lynda G., Howard, A. Fuchsia, Chia, Stephen K., Gotay, Carolyn C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042363/
https://www.ncbi.nlm.nih.gov/pubmed/29996816
http://dx.doi.org/10.1186/s12885-018-4644-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042363/
https://www.ncbi.nlm.nih.gov/pubmed/29996816
http://dx.doi.org/10.1186/s12885-018-4644-7

Ejemplares similares